An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
- Offered byUS Pharmacopoeia
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits at US Pharmacopoeia Overview
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
Through this course understand what is included on the USP COVID-19 Quality Assessment Toolkits
Duration | 60 days |
Total fee | Free |
Mode of learning | Online |
Schedule type | Self paced |
Official Website | Explore Free Course  |
Credential | Certificate |
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits at US Pharmacopoeia Highlights
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
- The four toolkits currently available include General Vaccine Chapters and Compendial Assays; mRNA Vaccines; Viral Vector Vaccines; and Inactivated Vaccines
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits at US Pharmacopoeia Course details
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
Skills you will learn
Who should do this course?
- For National regulatory authority staff
- For National control laboratory staff
- For Vaccine manufacturing quality control and assurance staff
- For Analytical laboratory scientists
What are the course deliverables?
- Understand the quality attributes for COVID-19 vaccine products and common tests used to ensure their quality
- Know where to access and download the toolkit on the USP website
- Know how to access the USP-NF using the complimentary subscription
More about this course
- As COVID-19 vaccines become available globally, it is important for countries to put measures in place to help ensure the quality of the vaccine products being used in their countries, especially those procured outside of authorized vaccine programs
- There are a growing number of reports of substandard or falsified (SF) COVID-19 medical products
- The WHO recommends that countries accept vaccines received directly through COVAX without the need for additional testing
- As the pandemic continues, however, there will be other avenues for vaccines acquisition, and it is advisable to perform some in-country testing on these vaccines to ensure their quality
- For some countries receiving vaccines, there may be additional local requirements for testing
- Although some countries are taking measures to control the entry of SF COVID-19 vaccine products, more work needs to be done
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits at US Pharmacopoeia Curriculum
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits at US Pharmacopoeia Faculty details
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
John F. Kokai-Kun
Director, External Scientific Collaboration, USP Ph.D. in Microbiology, University of Pittsburgh, School of Medicine
Sarita K. Acharya, M.S.
USP employee since 2019 Principal Scientist, Global Biologics M.S. in Biotechnology, University of Maryland Global Campus
Other courses offered by US Pharmacopoeia
An Introduction to USP?s COVID-19 Vaccine Quality Assessment Toolkits
at US Pharmacopoeia
Student Forum
Anything you would want to ask experts?
HealthcareHealthcare ManagementHealthAn Introduction to USP?s COVID-19 Vaccine Quality Assessment ToolkitsUseful Links
Know more about US Pharmacopoeia
Know more about Programs
- Medical Courses
- Public Health & Management
- Hospital Management Course
- Medical Transcription
- Perfusion Technology
- Diabetology
- Forensic Medical Science
- Dialysis Technology
- Cardiovascular Technology
- Cath Lab Technology
- BSc Operation Theatre Technology
- BSc in Perfusion Technology
- Physician Assistant
- BSc Physician Assistant
- BSc in Respiratory Care Technology